Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine. Sanofi and GSK have today signed agreements with the Government of Canada for the supply of up to 72 million doses of an adjuvanted COVID-19 vaccine, beginning in 2021.. To address a global health crisis of this magnitude, it takes...
ViiV Healthcare today announced findings from“ Here as I Am: A Listening Initiative with Latinx Gay and Bisexual Men Affected by HIV,” which found that for Latinx men, including cis and transgender men, who have sex with men, navigating sexual and cultural identity amid social pressures poses significant challenges to accessing healthcare.
RNS Number: 7977 Y GlaxoSmithKline PLC 11 September 2020 GlaxoSmithKline plc. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 6219 Y GlaxoSmithKline PLC 10 September 2020 GlaxoSmithKline plc. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
GlaxoSmithKline plc and Innoviva, Inc. announced the US Food and Drug Administration has approved a new indication for Trelegy Ellipta for the treatment of asthma in patients aged 18 years and older adding to its current license for use in patients with chronic obstructive pulmonary disease. Trelegy Ellipta is not indicated for relief of acute...
GlaxoSmithKline plc and Innoviva, Inc. announced the US Food and Drug Administration has approved a new indication for Trelegy Ellipta for the treatment of asthma in patients aged 18 years and older adding to its current license for use in patients with chronic obstructive pulmonary disease. Trelegy Ellipta is not indicated for relief of acute...
New asthma indication for Trelegy Ellipta introduces an important option for patients to the current treatment paradigm. LONDON& BURLINGAME, Calif.---- GlaxoSmithKline plc and Innoviva, Inc. announced the US Food and Drug Administration has approved a new indication for Trelegy Ellipta for the treatment of asthma in patients aged 18 years and older adding to...
New asthma indication for Trelegy Ellipta introduces an important option for patients to the current treatment paradigm. LONDON& BURLINGAME, Calif.---- GlaxoSmithKline plc and Innoviva, Inc. announced the US Food and Drug Administration has approved a new indication for Trelegy Ellipta for the treatment of asthma in patients aged 18 years and older adding to...
RNS Number: 5214 Y GlaxoSmithKline PLC 09 September 2020 GlaxoSmithKline plc. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 5037 Y GlaxoSmithKline PLC 09 September 2020 GlaxoSmithKline plc. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 9207 X GlaxoSmithKline PLC 03 September 2020 Issued: 3 September 2020, London, UK and Paris, France. Sanofi and GSK initiate Phase 1/ 2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate. A total of 440 healthy adults are being enrolled in the trial across 11 investigational sites in the United States..
RNS Number: 7145 X GlaxoSmithKline PLC 01 September 2020. The Company's issued share capital as at 31 August 2020 consisted of 5,385,069,877 shares of 25 pence each, of which 367,705,950 Ordinary Shares were held in Treasury.. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 0653 W GlaxoSmithKline PLC 13 August 2020 GlaxoSmithKline plc. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration approved Dovato as a complete regimen for the treatment of HIV-1 infection to replace the current antiretroviral regimen in adults who are virologically suppressed on a...
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration approved Dovato as a complete regimen for the treatment of HIV-1 infection to replace the current antiretroviral regimen in adults who are virologically suppressed on a...
GlaxoSmithKline Plc #GSK announced that the US Food and Drug Administration (FDA) has approved BLENREP as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor and an immunomodulatory agent. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. BLENREP is the first anti-BCMA (B-cell maturation antigen) therapy approved anywhere in the world.
RNS Number: 2974 V GlaxoSmithKline PLC 06 August 2020 Issued: 6 August 2020, London UK. FDA approves GSK's BLENREP for the treatment of patients with relapsed or refractory multiple myeloma. ·BLENREP is a first-in-class anti-BCMA therapy for patients whose disease has progressed despite prior treatment with an immunomodulatory agent, proteasome inhibitor...
GlaxoSmithKline plc announced the US Food and Drug Administration has approved BLENREP as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor and an immunomodulatory agent. This indication is...
RNS Number: 9473 U GlaxoSmithKline PLC 03 August 2020. The Company's issued share capital as at 31 July 2020 consisted of 5,385,053,327 shares of 25 pence each, of which 367,705,950 Ordinary Shares were held in Treasury.. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
GlaxoSmithKline Plc #GSK announced that along with Sanofi, the company is in advanced discussions with the European Commission (EC) for the supply of up to 300 million doses of a COVID-19 vaccine. Moreover, the vaccine candidate developed by Sanofi in partnership with GSK, is based on the recombinant proteinbased technology used by Sanofi to produce an influenza vaccine, and GSK's established adjuvant technology.
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    4.97B

Company Profile

UK-based GlaxoSmithKline is one of the world's leading pharmaceutical research companies. The company was created out of the merger between GlaxoWellcome and SmithKline Beecham in 2000.

Classification

Market Indices-
Watchlist